Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)
Positive interim clinical data further validate the modularity of Intellia’s industry-leading genome editing platform and its potential to target a...